Equities Analysts Set Expectations for Amgen Q4 Earnings

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at William Blair dropped their Q4 2025 earnings per share (EPS) estimates for shares of Amgen in a research report issued to clients and investors on Wednesday, November 5th. William Blair analyst M. Phipps now expects that the medical research company will earn $4.61 per share for the quarter, down from their prior estimate of $5.60. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen’s Q1 2026 earnings at $5.37 EPS, Q2 2026 earnings at $5.89 EPS, Q3 2026 earnings at $5.57 EPS, Q4 2026 earnings at $5.06 EPS, FY2027 earnings at $22.61 EPS and FY2028 earnings at $22.78 EPS.

Several other brokerages also recently weighed in on AMGN. Wells Fargo & Company raised their price target on Amgen from $280.00 to $300.00 and gave the company an “overweight” rating in a report on Wednesday. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 27th. Raymond James Financial started coverage on shares of Amgen in a report on Wednesday, September 3rd. They set a “market perform” rating on the stock. Citigroup boosted their price objective on shares of Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. Finally, Bank of America upped their price objective on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday, September 26th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $308.83.

Amgen Stock Up 0.8%

AMGN stock traded up $2.52 on Friday, reaching $318.11. 276,829 shares of the company traded hands, compared to its average volume of 2,726,369. The firm has a fifty day simple moving average of $289.29 and a 200-day simple moving average of $288.18. The company has a market cap of $171.26 billion, a P/E ratio of 25.97, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45. Amgen has a one year low of $253.30 and a one year high of $335.88. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the prior year, the company earned $5.58 earnings per share. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.

Hedge Funds Weigh In On Amgen

Several large investors have recently made changes to their positions in the business. OLD National Bancorp IN boosted its holdings in Amgen by 296.2% during the 2nd quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock valued at $5,027,000 after acquiring an additional 13,460 shares during the period. Trinity Legacy Partners LLC lifted its position in shares of Amgen by 3.9% during the first quarter. Trinity Legacy Partners LLC now owns 16,132 shares of the medical research company’s stock worth $5,026,000 after purchasing an additional 612 shares during the last quarter. Founders Financial Alliance LLC boosted its stake in shares of Amgen by 2.7% during the first quarter. Founders Financial Alliance LLC now owns 1,577 shares of the medical research company’s stock valued at $491,000 after purchasing an additional 42 shares during the period. Stephens Inc. AR grew its holdings in shares of Amgen by 14.2% in the second quarter. Stephens Inc. AR now owns 95,731 shares of the medical research company’s stock worth $26,729,000 after purchasing an additional 11,888 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp increased its stake in Amgen by 2.7% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 277,397 shares of the medical research company’s stock worth $86,423,000 after buying an additional 7,308 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.76% of the company’s stock.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 3.0%. Amgen’s dividend payout ratio (DPR) is 73.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.